Oculis Holding AG (NASDAQ:OCSAW – Get Free Report) rose 11.1% during trading on Wednesday . The stock traded as high as $5.00 and last traded at $5.00. 277 shares were traded during mid-day trading, a decline of 95% from the average daily volume of 5,654 shares. The stock had previously closed at $4.50.
Oculis Stock Up 11.1%
The business has a fifty day simple moving average of $4.44 and a two-hundred day simple moving average of $12.13.
About Oculis
Oculis SA is a clinical‐stage biopharmaceutical company focused on developing disease‐modifying therapies for serious eye diseases. Utilizing its proprietary ocular formulation technologies, the company is advancing a pipeline of small‐molecule product candidates designed for topical or injectable delivery. Lead programs include OCS-01, a topical eye drop candidate for diabetic macular edema, and OCS-02, targeting diabetic retinopathy. Oculis also has OCS-05 in development for optic neuropathies and other retinal disorders, reflecting its commitment to addressing a broad spectrum of unmet needs in ophthalmology.
Founded in 2016 and headquartered in Geneva, Switzerland, Oculis operates research and development facilities in Europe and the United States.
Featured Stories
- Five stocks we like better than Oculis
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
